

104 - 9295 198th Street
Langley BC V1M3J9
Tel: 604.336.0881
Email: news@abattis.com



Abattis Closes the Warrant Exercise Incentive Program & Private Placement

Vancouver, BC – February 1, 2017 – Abattis Bioceuticals Corp., (“**ATT**” or the “**Company**”) (OTCQB: ATTBF) (CSE: ATT) is pleased to announce the close of its Warrant Exercise Incentive Program (the “**Program**”) under which the Company has issued 3,549,080 common shares on the exercise of Eligible Warrants for gross proceeds of \$295,417.20 in two tranches.

The Program encouraged the exercise of common share purchase warrants of the Company which were issued as part of the Company’s private placements which closed on August 19, 2015 and December 3, 2015, respectively (collectively, the “**Eligible Warrants**”). Each Eligible Warrant is currently exercisable for one common share (each a “**Common Share**”) of the Company at a price of \$0.09 per Common Share in respect of the August 19, 2015 closing and at a price of \$0.07 per Common Share in respect of the December 3, 2015 closing, and expires at 5:00 p.m. (EST) on August 19, 2017 and December 3, 2017, respectively.

Pursuant to the Program, the Company offered each holder of Eligible Warrants (“**Warrant Holders**”) that exercised Eligible Warrants during an early exercise period, which has now ended, (the “**Early Exercise Period**”) an additional common share purchase warrant (each an “**Incentive Warrant**”), with each Incentive Warrant entitling the Warrant Holder to purchase one additional Common Share until 5:00 p.m. (PST) on January 18, 2019 and January 31, 2019, respectively for each tranche, at a price of \$0.15 per Common Share.

Eligible Warrants that remain unexercised following the completion of the Early Exercise Period (defined below) will continue to be exercisable for Common Shares on the original terms as they existed prior to the Program.

The Incentive Warrants and any Common Shares issuable on the exercise thereof will be subject to a four-month hold period from the date of issuance of the Incentive Warrants pursuant to applicable Canadian securities laws.

Funds received will be used to complete the build and outfitting of the Company’s Health Canada Controlled Substances testing facility in the lower mainland. A private placement in the amount of \$500,000 was announced on December 8, 2016 to augment any funds received through the Program. The Company also closed \$50,000 of the private placement by issuing units comprising 433,000 common shares at a deemed price of \$0.1155 per share, and 433,000 share purchase warrants exercisable into the same number of common shares at a price of \$0.1875. The warrants from the December 8 private placement are exercisable up to and including July 1, 2018. Abattis opted to close the private placement at \$50,000 as it had raised enough capital for the Northern Vine program and did not wish to further dilute shareholdings at the current market price.

Northern Vine labs, the Company’s Health Canada Controlled Substance testing facility, is set to benefit from the recent articles that have been published by prominent newspapers such as The Globe and Mail. These articles have put an emphasis on the need for more oversight by Health Canada with regard to

assuring the proper tests have been completed. It also noted the need for a wider array of pesticides to be tested for.

The article also noted the need for Health Canada to allow for the current grey market dispensaries to get their product tested at Licensed Facilities. Currently the grey market represents a significantly large portion of marijuana consumers in Canada and although many have shut down there is still a number of them operating.

You can view the article at this link – [Globe and Mail Article](#)

About Abattis Bioceuticals Corp.

Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company also is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

About Northern Vine Canada Inc.

Northern Vine Labs™ is licensed by Health Canada for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purposes of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the Canadian market.

About Vergence Visionary Bioceuticals Corp.

Vergence Visionary Bioceuticals, dba Vergence Sales and Marketing Group, is a wholly owned subsidiary of Abattis Bioceuticals Corp. based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast-growing market for natural, safe and effective natural products that meet unmet wellness needs.

"Rene David"

Rene David, CFO

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.